Anavex Life Sciences Corp (AVXL)

[falconer66a]

The question of Aducanumab (Biogen) and A2-73 synergism is interesting.

Aducanumab is a monoclonal antibody; chemically unrelated to Anavex 2-73. It binds to or helps clear beta amyloid aggregations.

I can see no chemical reason either of these molecules would favorably enhance the efficacy of the other. They work so differently, with differing cellular structures and chemistries.

My bets are that A2-73 will work very effectively by itself; that concomitant dosings with Aducanumab might improve clinical outcomes by only the smallest of fractions, if at all.

Key is this. A2-73 has caused no severe adverse outcomes; Aducanumab has caused, among other things, brain swelling, which by no means is minor or inconsequential. The threat of such adverse events over rides, I believe, whatever minor improvements it might provide.

Clinical trials will determine all of this, of course.